Treatment of HCV in Patients with Renal Failure

Harmit Kalia, Patricia M. Lopez, Paul Martin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

There continues to be a high prevalence of hepatitis C virus infection in patients with chronic kidney disease (CKD) on maintenance hemodialysis, despite screening of blood products and precautions to prevent the transmission of viral hepatitis within dialysis units. In addition, an increased rate of mortality from liver disease has been observed in infected patients on long-term dialysis, despite the frequent absence of biochemical dysfunction. Hepatitis C-infected renal transplant recipients have diminished patient and graft survivals compared to uninfected controls. Treatment with interferon in renal transplant candidates has resulted in sustained viral responses that have been long lasting even after subsequent renal transplant. A major concern limiting the use of interferon following renal transplant is graft dysfunction due to rejection. Ribavirin's induction of hemolytic anemia is the major reason why it is avoided in patients with CKD. Cautious use of reduced-dose ribavirin in small studies has been promising in these patients with close monitoring of hematocrit and additional measures to enhance compensatory erythropoiesis.

Original languageEnglish
Pages (from-to)628-633
Number of pages6
JournalArchives of Medical Research
Volume38
Issue number6
DOIs
StatePublished - Aug 1 2007
Externally publishedYes

Fingerprint

Renal Insufficiency
Transplants
Kidney
Ribavirin
Chronic Renal Insufficiency
Interferons
Dialysis
Therapeutics
Erythropoiesis
Hemolytic Anemia
Graft Survival
Virus Diseases
Hepatitis C
Hematocrit
Hepacivirus
Hepatitis
Renal Dialysis
Liver Diseases
Maintenance
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of HCV in Patients with Renal Failure. / Kalia, Harmit; Lopez, Patricia M.; Martin, Paul.

In: Archives of Medical Research, Vol. 38, No. 6, 01.08.2007, p. 628-633.

Research output: Contribution to journalArticle

Kalia, Harmit ; Lopez, Patricia M. ; Martin, Paul. / Treatment of HCV in Patients with Renal Failure. In: Archives of Medical Research. 2007 ; Vol. 38, No. 6. pp. 628-633.
@article{34fedfd8da4a437cbff5c7880a6a23cf,
title = "Treatment of HCV in Patients with Renal Failure",
abstract = "There continues to be a high prevalence of hepatitis C virus infection in patients with chronic kidney disease (CKD) on maintenance hemodialysis, despite screening of blood products and precautions to prevent the transmission of viral hepatitis within dialysis units. In addition, an increased rate of mortality from liver disease has been observed in infected patients on long-term dialysis, despite the frequent absence of biochemical dysfunction. Hepatitis C-infected renal transplant recipients have diminished patient and graft survivals compared to uninfected controls. Treatment with interferon in renal transplant candidates has resulted in sustained viral responses that have been long lasting even after subsequent renal transplant. A major concern limiting the use of interferon following renal transplant is graft dysfunction due to rejection. Ribavirin's induction of hemolytic anemia is the major reason why it is avoided in patients with CKD. Cautious use of reduced-dose ribavirin in small studies has been promising in these patients with close monitoring of hematocrit and additional measures to enhance compensatory erythropoiesis.",
author = "Harmit Kalia and Lopez, {Patricia M.} and Paul Martin",
year = "2007",
month = "8",
day = "1",
doi = "10.1016/j.arcmed.2006.12.010",
language = "English",
volume = "38",
pages = "628--633",
journal = "Archives of Medical Research",
issn = "0188-4409",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Treatment of HCV in Patients with Renal Failure

AU - Kalia, Harmit

AU - Lopez, Patricia M.

AU - Martin, Paul

PY - 2007/8/1

Y1 - 2007/8/1

N2 - There continues to be a high prevalence of hepatitis C virus infection in patients with chronic kidney disease (CKD) on maintenance hemodialysis, despite screening of blood products and precautions to prevent the transmission of viral hepatitis within dialysis units. In addition, an increased rate of mortality from liver disease has been observed in infected patients on long-term dialysis, despite the frequent absence of biochemical dysfunction. Hepatitis C-infected renal transplant recipients have diminished patient and graft survivals compared to uninfected controls. Treatment with interferon in renal transplant candidates has resulted in sustained viral responses that have been long lasting even after subsequent renal transplant. A major concern limiting the use of interferon following renal transplant is graft dysfunction due to rejection. Ribavirin's induction of hemolytic anemia is the major reason why it is avoided in patients with CKD. Cautious use of reduced-dose ribavirin in small studies has been promising in these patients with close monitoring of hematocrit and additional measures to enhance compensatory erythropoiesis.

AB - There continues to be a high prevalence of hepatitis C virus infection in patients with chronic kidney disease (CKD) on maintenance hemodialysis, despite screening of blood products and precautions to prevent the transmission of viral hepatitis within dialysis units. In addition, an increased rate of mortality from liver disease has been observed in infected patients on long-term dialysis, despite the frequent absence of biochemical dysfunction. Hepatitis C-infected renal transplant recipients have diminished patient and graft survivals compared to uninfected controls. Treatment with interferon in renal transplant candidates has resulted in sustained viral responses that have been long lasting even after subsequent renal transplant. A major concern limiting the use of interferon following renal transplant is graft dysfunction due to rejection. Ribavirin's induction of hemolytic anemia is the major reason why it is avoided in patients with CKD. Cautious use of reduced-dose ribavirin in small studies has been promising in these patients with close monitoring of hematocrit and additional measures to enhance compensatory erythropoiesis.

UR - http://www.scopus.com/inward/record.url?scp=34347220500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347220500&partnerID=8YFLogxK

U2 - 10.1016/j.arcmed.2006.12.010

DO - 10.1016/j.arcmed.2006.12.010

M3 - Article

VL - 38

SP - 628

EP - 633

JO - Archives of Medical Research

JF - Archives of Medical Research

SN - 0188-4409

IS - 6

ER -